Shares of GSK plc (LON:GSK – Get Free Report) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is GBX 1,805.83 ($23.10).
Several equities analysts have issued reports on GSK shares. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. Berenberg Bank decreased their target price on GSK from GBX 1,820 ($23.28) to GBX 1,600 ($20.47) and set a “buy” rating for the company in a research report on Friday, November 29th.
Check Out Our Latest Stock Report on GSK
GSK Price Performance
GSK (LON:GSK – Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.
Insiders Place Their Bets
In other GSK news, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction on Friday, December 20th. The shares were bought at an average price of GBX 1,315 ($16.82) per share, with a total value of £19,725 ($25,233.47). Also, insider Emma Walmsley sold 120,653 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.59), for a total value of £1,753,088.09 ($2,242,660.98). 1.61% of the stock is owned by insiders.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
- Five stocks we like better than GSK
- What Are Trending Stocks? Trending Stocks Explained
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Tesla Stock: Finding a Bottom May Take Time
- What is the NASDAQ Stock Exchange?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.